Vicriviroc

DRUG8 trials

Sponsors

Merck Sharp & Dohme LLC, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Acquired Immunodeficiency SyndromeColorectal NeoplasmsHIV Infections

Phase 1

Effect of Vicriviroc on HIV Ribonucleic Acid (RNA) Levels in Cerebrospinal Fluid (Study P05241)

CompletedNCT00632073

Merck Sharp & Dohme LLCHIV Infections

Start: 2008-03-31End: 2010-03-31Updated: 2015-02-23

Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents

CompletedNCT00766597

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2009-08-31End: 2010-08-31Updated: 2021-11-05

Phase 2

Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)

CompletedNCT00551018

Merck Sharp & Dohme LLCHIV Infections

Start: 2007-12-31End: 2010-10-31Updated: 2015-02-06

Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)

CompletedNCT00551330

Merck Sharp & Dohme LLCAcquired Immunodeficiency Syndrome, HIV Infections

Start: 2007-09-30End: 2010-05-31Updated: 2015-12-21

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

CompletedNCT03631407

Merck Sharp & Dohme LLCColorectal Neoplasms

Start: 2018-09-24End: 2021-06-08Updated: 2024-11-21

Phase 3

Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285

WithdrawnNCT00243568

Merck Sharp & Dohme LLCAcquired Immunodeficiency Syndrome, HIV Infections

Start: 2005-09-01Updated: 2019-09-12

Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)

CompletedNCT00474370

Merck Sharp & Dohme LLCAcquired Immunodeficiency Syndrome, HIV Infections

Start: 2007-05-15End: 2010-10-26Updated: 2022-08-30

Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)

CompletedNCT00523211

Merck Sharp & Dohme LLCAcquired Immunodeficiency Syndrome, HIV Infections

Start: 2007-07-31End: 2011-03-31Updated: 2015-09-25

Related Papers

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer.

2024-05-136 citations

Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials.

2012-05-2429 citations